CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies

CD19 chimeric antigen receptor T cell therapy for haematological malignancies

(2015) Sara Ghorashian et al.   BRITISH JOURNAL OF HAEMATOLOGY

Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells

(2015) B L Levine   CANCER GENE THERAPY

Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model

(2015) H Almåsbak et al.   GENE THERAPY

Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor

(2015) Kurt Schönfeld et al.   MOLECULAR THERAPY

CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia

(2015) Judith Weiland et al.   PEDIATRIC BLOOD & CANCER

Cellular Immunotherapy for Carcinoma Using Genetically Modified EGFR-Specific T Lymphocytes

(2015) Xikun Zhou et al.   NEOPLASIA

Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies

(2014) Saar Gill et al.   IMMUNOLOGICAL REVIEWS

Are natural killer cells superior CAR drivers?

(2014) Hans Klingemann   OncoImmunology

Valproic acid upregulates NKG2D ligand expression and enhances susceptibility of human renal carcinoma cells to NK cell-mediated cytotoxicity

(2013) Fengqiang Yang et al.   Archives of Medical Science

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

(2013) J. N. Kochenderfer et al.   BLOOD

Treatment of patients with advanced cancer with the natural killer cell line NK-92

(2013) Torsten Tonn et al.   CYTOTHERAPY

Modification of Hematopoietic Stem/Progenitor Cells with CD19-Specific Chimeric Antigen Receptors as a Novel Approach for Cancer Immunotherapy

(2013) Satiro Nakamura De Oliveira et al.   HUMAN GENE THERAPY

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

(2013) J Chu et al.   LEUKEMIA

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity

(2013) Laurent Boissel et al.   OncoImmunology

Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications

(2012) Natalia Lapteva et al.   CYTOTHERAPY

Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene Therapy

(2012) Tolga Sutlu et al.   HUMAN GENE THERAPY

Redirecting T Cells to Ewing's Sarcoma Family of Tumors by a Chimeric NKG2D Receptor Expressed by Lentiviral Transduction or mRNA Transfection

(2012) Manfred Lehner et al.   PLoS One

Human NKG2D-ligands: cell biology strategies to ensure immune recognition

(2012) Lola Fernández-Messina et al.   Frontiers in Immunology

Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor

(2011) D V Tassev et al.   CANCER GENE THERAPY

Genetically Modified T cells Targeting Interleukin-11 Receptor  -Chain Kill Human Osteosarcoma Cells and Induce the Regression of Established Osteosarcoma Lung Metastases

(2011) G. Huang et al.   CANCER RESEARCH

Infusing CD19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-Cell Transplantation for Advanced B-Lymphoid Malignancies

(2011) Partow Kebriaei et al.   HUMAN GENE THERAPY

NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin

(2011) Ruth Esser et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells

(2011) K Mihara et al.   LEUKEMIA

Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens

(2011) Laurent Boissel et al.   LEUKEMIA & LYMPHOMA

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients

(2010) Uwe Siegler et al.   CYTOTHERAPY

Long–term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors

(2009) Bart A. Nijmeijer et al.   EXPERIMENTAL HEMATOLOGY

Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells

(2009) Laurent Boissel et al.   LEUKEMIA RESEARCH

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

(2008) S. Arai et al.   CYTOTHERAPY

NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G

(2008) G Maki et al.   LEUKEMIA